Introduction Significance of Treatment with Intrathecal Baclofen
In recent years, intrathecal baclofen (ITB) has attained an important role in the interdisciplinary approach to treat severe spasticity and dystonia in children.
There are considerable differences between the various clinical centers within Germany with regard to the local setting and contributing specialist departments. Patients are looked after in departments and outpatient clinics for neuropediatrics as well as in so-called social pediatric centers, where interdisciplinary teams care for children with special needs. These centers are usually situated close to children's hospitals. Some pediatric neurorehabilitation specialty clinics are amongst the most experienced centers in Germany. Implantation of the pump system is usually the responsibility of the neurosurgery departments, rarely of the orthopedics or anesthesia departments. Looking after patients with pump implants in addition involves specialists in anesthesiology, pediatric intensive care, spinal surgery, and orthopedics. For some patients, effective palliative care requires an interdisciplinary approach. ITB centers should be able to draw on interdisciplinary cooperation between all specialist units involved (integrated approach). To date, there is neither a clinical guideline nor a uniform medical care concept for patients assigned to ITB treatment.
The use of ITB in children is licensed for children older than 4 years and requires obligatory prior testing with oral baclofen. In clinical practice, physicians are often confronted with situations where strictly following these criteria would not meet patients' needs. Some young children who are below the age of 4 years were presented with conditions requiring urgent treatment. In other patients, a delay of the initiation of therapy (e.g., for prior testing) would be to the disadvantage of the patient (see also section Aims of Consensus and Methods).
For application in children and adolescents, ITB is registered only for patients aged between 4 and 18 years suffering from severe chronic spasticity of cerebral or spinal origin (related to brain injury, multiple sclerosis, and spinal cord affections), under the provision that there is no response to orally administered antispastic agents (including oral baclofen) and/or that the effective oral dose leads to intolerable side effects (see Summary of Product Characteristics "Lioresal ® intrathecal," January 2011).
1 Some of the indications and fields of application listed in this consensus table are outside the approved registration. In such cases, it is imperative to carefully explain the proposed treatment to parents or legal guardian and obtain their written informed consent for each individual patient. Treatment with ITB outside the constraints of the registered indications should not be withheld unethically. Such "off-label use" of drugs is common in pediatric practice for a range of different clinical conditions and drugs, and is categorized as individual "compassionate use" under the responsibility of the treating physician. Off-label-use of baclofen for the treatment of children and adolescents is based on current evidence from controlled studies as well as consensus recommendations published by national and international experts and medical societies. Intrathecal application of baclofen requires specific experience and knowledge regarding correct indication, dosage, and application technique.
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Abstract
In recent years, intrathecal baclofen (ITB) has attained an important role in the treatment of severe spasticity and dystonia in children. There are principal differences between the use of ITB in children and its use in neurology and oncology in adults. Here, we present a consensus report on best practice for the treatment of severe spastic and dystonic movement disorders with ITB. Using a problem-orientated approach to integrate theories and methods, the consensus was developed by an interdisciplinary group of experienced ITB users and experts in the field of movement disorders involving 14 German centers. On the basis of the data pooled from more than 400 patients, the authors have summarized their experience and supporting evidence in tabular form to provide a concise, but still a comprehensive information base that represents our current understanding regarding ITB treatment options in children and adolescents. The level of evidence of clinical trials was rated level I-V according to AACPDM methodology to develop systematic reviews of treatment interventions, revision 1.2, 2008. The level of each clinical study is noted after the citation number.
• Level I: Systematic review of RCTs, large RCTs (with narrow confidence intervals; n > 100).
• Level II: Smaller RCTs (with wider confidence intervals; n < 100), systematic reviews of cohort studies, "Outcomes research" (very large ecological studies).
• Level III: Cohort studies (must have concurrent control group), systematic reviews of case-control studies.
• Level IV: Case series, cohort study without concurrent control group, case-control study.
• Level V: Expert opinion, case study or report; bench research, expert opinion based on theory or physiologic research, common sense/anecdotes. 
Aims of Consensus and Methods
The range of neuropediatric disorders for which treatment with ITB is indicated, as well as the practical approach clearly differs from applications in adult neurology and oncology. This calls for a thorough work-up of the topic with regard to the specific requirements in pediatrics. The consensus presented here aims to (1) summarize and evaluate the available studies (focusing on clinical studies in humans with an emphasis on children and adolescents) in terms of evidence-based medicine and (2) describe the practical approach in German-speaking treatment centers (practicebased evidence). The methodology of rating clinical trials is outlined in ►Table 1. We explicitly have included off-label indications. The aim of this study is to present the full range of current practical experience. Because of its complexity and adaptation to individual patient needs, it is impossible to present recommendations for ITB treatment that would be universally applicable to each individual patient and situation. The introductory text (10 sections) and the 10 consensus tables are intended to provide orientation and allow the reader to become familiar with the current range of applications and practical approaches. 
Indications
In principal, indications for treatment with ITB include severe spasticity of spinal or cerebral origin, and severe dystonia uncontrollable with oral medication. Accordingly, there is a broad range of disorders that can be considered for treatment with ITB. It has to be acknowledged that the vast majority of clinical studies with ITB including the studies with the highest evidence level investigated patients with primarily spastic movement disorders. For patients with severe dystonia, evidence for this treatment intervention is much less, and the treatment effect and its significance in daily life of the patient are much more difficult to predict.
Before establishing an indication, the treating physician should (1) clarify the underlying etiology of the movement disorder, (2) classify the movement disorder (spasticity, dystonia, other forms of hypertonia, degree of severity, and distribution pattern) using suitable assessment tools, and (3) specify any comorbidities that might potentially aggravate spasticity. For details of indications and supporting references, please refer to ►Table 2.
Selection of Patients
Classification of patients with cerebral palsy (and correspondingly of many patients with other movement disorders) using the Gross Motor Function Classification System (GMFCS) has proven useful because a patient's classification grade (I-III vs. IV/V) is of central importance when deciding on achievable therapeutic goals for this patient. Data on the efficacy of ITB mostly relate to patients classified as GMFCS grades IV and V. In those patients, therapy primarily aims at the functional level to reduce spasticity and at the activity level to improve general well being, reduce pain, and facilitate patient care and everyday activities, acknowledged as important aspects for quality of life. Thus, ITB essentially relieves symptoms for a range of disorders but has no influence on the medical and therapeutic aftercare within reasonable distance from the patients' place of living. While treatment of patients younger than 4 years constitutes off-label use, such a young age is not per se a contraindication. ITB is justified for children younger than 4 years after cerebral hypoxia but also in all other disorders associated with muscular hypertonia resistant to therapy by any other means. Over the years, this group of authors has accumulated experience in the treatment of more than 75 such patients.
Contrary to the Summary of Product Characteristics of baclofen 1 treatment with ITB after traumatic brain injury should be considered not only "when spasticity has stabilized (i.e., at least 1 year after injury)" but already when generalized spasticity is developing and is affecting the course of rehabilitation. Epilepsies, including difficult to treat epilepsies, are not per se contraindicate for treatment with ITB. The pros and cons, that is, the need for treating the hypertonia versus the risk of aggravating epileptic seizures, have to be carefully Note: For details on levels of evidence, please refer to ►Table 1.
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weighed against each other, taking into account that ITB may improve the patient's well being and sleep and thereby positively influence epilepsy. We wish to point out that parents and any other family members and caregivers must be comprehensively informed about the mode of action, technique of administration, and possible adverse side effects. Caregivers must be able to recognize any side effects or complications of therapy. Therefore, clear and precise information is indispensable. The consensus group has prepared a comprehensive information brochure.
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Testing
For testing before final pump implantation, patients should be admitted to a specialized center with adequate experience. The testing phase should be performed in an inpatient setting under close supervision by appropriately qualified specialists. Prior oral baclofen to test tolerability is mandatory.
ITB is administered either via lumbar puncture or via a spinal catheter. The purpose of the test is to detect any intolerance and to assess the effect on muscle tone, rather than predicting final overall efficacy.
Vials of 50 µg/mL baclofen are available for bolus testing. The initial dose for puncture is 25 to 50 µg. The onset of action occurs after approximately 30 to 90 minutes and the maximum effect is reached after approximately 4 hours. The effect lasts 8 to 24 hours. Therefore, to reduce the risk of adverse effects, a second testing with double the initial dose should not be done earlier than 24 hours after the previous injection. As a general rule, the bolus dose should not exceed 100 µg.
In cases where it is difficult to predict the clinical outcome and its effect on the patient's everyday life, the test injection should be done via a spinal catheter. To reduce the risk of infection, the catheter should be tunneled under the skin for approximately 3 cm from the actual puncture site. Baclofen may be administered in the form of repeated Note: For details on levels of evidence, please refer to ►Table 1.
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bolus injections or continuously injected over several days using an external pump. When testing was done via a spinal catheter, implantation of the final pump should be done after an interval of at least 4 to 6 weeks after removal of the catheter. In some patients, prior testing may be omitted if the indication can be clearly established and the course of action well justified. Details on methodology of testing can be found in ►Table 4.
Implantation
In children, the pump is always placed in an abdominal pouch under general anesthesia. A gastric tube does not constitute a contraindication but should always be planned ahead of pump implantation. The pump is implanted subcutaneously, or subfascially. Positioning of the catheter tip may vary depending on the underlying problems. In lower limbs accentuated tetraplegia, some authors recommend to place the tip at Th10-Th12, in tetraplegia at C5-Th2, and in generalized dystonia at C1-C4. Other authors do not see any differences in drug efficacy between different catheter positions and routinely place the tip in the middle to upper thoracic region. Some aspects of implantation procedure are outlined in ►Supplementary Table S1 65-73 (online-only).
Dose
Baclofen is a GABA-B agonist. The muscle-relaxing effect is primarily due to an increase of presynaptic inhibition at the spinal level and thus a reduction of mono-and polysynaptic reflex transmission. Intrathecal administration, bypassing the blood-brain barrier, allows 100-to 1,000-fold lower doses than those used in oral administration. Nevertheless, the possibility of central effects cannot be ruled out (see section Side Effects and Troubleshooting). There is no definite correlation between the baclofen concentration in cerebrospinal fluid and the clinical effect. It therefore makes little sense to measure drug concentration in cerebrospinal fluid. The most suitable dosage has to be determined individually and for each patient based on the observed therapeutic efficacy. Specifics on dosage can be found in ►Table 5.
Postimplantation Phase, Aftercare
Straight after pump implantation, the dose should be adjusted while closely monitoring the patient. This is best done while the patient still remains in hospital but in exceptional care situations also may be done in an outpatient setting. In parallel, a reduction of oral antispastic medication should be attempted.
ITB may lead to deterioration of trunk control. Accelerated progression of scoliosis during treatment with ITB has been described and controversially discussed in the literature. We recommend regular clinical and radiological checkup in 3 to 6 months' intervals. Further parameters to be regularly reviewed are as follows: Progress toward therapeutic goals, use of aids and orthoses, and indications for combination with other treatment options (e.g., botulinum toxin, orthopedic interventions, etc.).
Control of pump function, fill-up of the pump reservoir, and dose adjustments during the course of treatment may be done in the outpatient unit by appropriately trained physicians. Refill intervals depend on the reservoir volume of the pump and the administered dosage, and are generally between 2 and 6 months. Longer intervals should be avoided because the solution in the pump may become unstable. If using high doses, shorter refill intervals as far down as every 3 weeks may be required. Details are provided in Supplementary Table S2 78-82
(online-only).
Side Effects and Troubleshooting
As with all surgical interventions, perioperative complications may occur already during pump implantation but are altogether rare. Because of comorbidities, particular attention should be given to the anesthesiologic risk.
Patient and caregivers as well as physicians and therapists treating the patient should be alerted to a possible dysfunction of the implanted system. If symptoms of a patient raise suspicion, we recommend to successively check for any deficiencies, such as, incorrect catheter positioning or leakage, and to take immediate corrective action. We highly recommend close cooperation between conservatively and operatively treating physicians, such as pediatric neurologist and neurosurgeon. Pump pouch and catheter are prone to microbial contamination. Special care should be taken to maintain aseptic conditions when refilling the pump. Side effects of ITB are primarily dose dependent. Overdosing can occur especially during test and dose adjustment phases. In addition, errors in pump programming or confusion of drug concentrations should be considered as a possible source for overdosing. Frequently observed symptoms are as follows: Pronounced muscular hypotonia, arterial hypotension, tiredness, headaches, dizziness, urinary retention, nausea, and vomiting. Overdosing may lead to impaired consciousness and respiratory insufficiency requiring artificial respiration. The best counteraction is to treat the patient symptomatically in the intensive care unit and to initiate a stepwise and intermittent reduction of baclofen supply (beware of withdrawal symptoms!). The authors do not consider drawing of cerebrospinal fluid with the aim to lower the baclofen concentration in CSF, or parenteral administration of physostigmine as a suitable means for treating overdose symptoms.
ITB may cause a reduced bowel movements and thereby intestinal obstruction. During test and dose adjustment phases, therefore, micturition and bowel function should be carefully monitored and persistently treated if symptoms appear.
Withdrawal symptoms typically appear as a result of malfunctions in the catheter system, a too low level of the infusion solution in the pump reservoir or a too low battery level. The withdrawal symptoms are as follows: Increasing muscle tone, restlessness, vomiting, insomnia, confusion, pruritus, and finally convulsions up to the point of multiorgan failure. Relevant aspects of this important topic are highlighted in ►Table 6. Abbreviations: C, consensus statement; GMFCS, gross motor function classification system; ITB, intrathecal baclofen.
Note: For details on levels of evidence, please refer to ►Table 1.
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Documentation
With implantation of a medical device, the treating physician is obliged to provide parents or the legal guardian with a clearly written patient information document which usually comes along with the pump implanted. Primarily for the benefit of the patient's safety, clear documentation of the implanted device, dosage, refill interval, and battery status has a high priority. Some suggestions can be found in ►Table 8. Information about possible side effects The medical report should also draw attention to the possibility of inadvertent drug overdosing or withdrawal and describe the associated symptoms. Furthermore, the medical report should specify contact persons and a phone number through which a specialist is always within reach.
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